Article
Oncology
Anand Khadse, Vilde D. Haakensen, Laxmi Silwal-Pandit, Julian Hamfjord, Patrick Micke, Johan Botling, Odd Terje Brustugun, Ole Christian Lingjaerde, Aslaug Helland, Elin H. Kure
Summary: LOH in KRAS is associated with prognosis in early-stage lung adenocarcinoma, especially in cases with mutations. Patients with both KRAS mutation and LOH have a better prognosis compared to those with only KRAS mutation.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Chi Zhang, Ran Liu, Wei-Han Zhang, Xin-Zu Chen, Kai Liu, Kun Yang, Xiao-Long Chen, Lin-Yong Zhao, Zhi-Xin Chen, Zong-Guang Zhou, Jian-Kun Hu
Summary: The study found that patients with signet ring cell gastric cancer are typically younger and more commonly female compared to those with non-signet ring cell gastric cancer. For early stage signet ring cell gastric cancer patients, they have a lower lymph nodes metastasis rate and comparable prognosis with non-signet ring cell cancers; however, in advanced tumor stage, signet ring cell gastric cancer has a significantly worse prognosis.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Malin Enblad, Peter Pal Egerszegi, Helgi Birgisson, Tobias Sjoblom, Bengt Glimelius, Joakim Folkesson
Summary: Signet ring cell (SRC) carcinoma of colorectal and appendiceal cancer is rare but has the poorest prognosis. The prognostic relevance of a SRC component <50% is unclear. This study found that SRCs, both = 50% and <50%, were associated with aggressive histopathological features, advanced stages, and peritoneal metastases. It suggests that information about the presence of SRCs should be routinely registered to aid our understanding of SRCs in these cancers.
Article
Oncology
Yangkun Wang, Yingying Li, Bin Wang, Dongmei Ran, Chaoya Zhu, Ping Li, Bo Jiang, Sunan Wang
Summary: This study investigated the early onset, development, and histological features of gastric signet-ring cell carcinoma (SRCC). The results showed that gastric mucosa infection, especially by Helicobacter pylori, can cause massive cell proliferation and transformation in specific areas of the stomach. SRCC grows infiltratively and can differentiate into various types of adenocarcinoma with signet-ring cell differentiation.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Nandie Wu, Ying Huang, Fangcen Liu, Xingyun Xu, Baorui Liu, Jia Wei
Summary: The study showed the significant role of KRAS gene in signet-ring cell carcinoma (SRCC), with patients harboring KRAS mutations exhibiting lower survival rates and increased sensitivity to MEK and mTOR inhibitors. The findings suggest the therapeutic potential of targeting tumors through inhibition of the MEK and mTOR pathways in SRCC.
JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Shujun Jiang, Yanran Wu, Wenjie Wei, Zi Wang, Qi Wang
Summary: This report describes a rare case of colonic metastasis from primary lung signet ring cell adenocarcinoma (SRCA). The patient showed positive response to innovative treatment strategy.
ONCOTARGETS AND THERAPY
(2022)
Article
Biochemistry & Molecular Biology
Chune Yu, Dan Luo, Jing Yu, Min Zhang, Xiaobo Zheng, Guangchao Xu, Jiaxin Wang, Huiling Wang, Yufei Xu, Ke Jiang, Jie Xu, Xuelei Ma, Jing Jing, Hubing Shi
Summary: The study identified GRB7-PLK1 as a crucial axis mediating RTKs, resulting in tolerance to MEK inhibitors. Therefore, PLK1 is a promising target for enhancing the clinical treatment of CRC patients with KRAS mutations by synergizing with MEK inhibitors.
Article
Medicine, Research & Experimental
Tianxia Li, Osamu Kikuchi, Jin Zhou, Yichen Wang, Babita Pokharel, Klavdija Bastl, Prafulla Gokhale, Aine Knott, Yanxi Zhang, John G. Doench, Zandra V. Ho, Daniel V. T. Catenacci, Adam J. Bass
Summary: Gastroesophageal adenocarcinomas (GEAs) frequently exhibit amplification of KRAS gene, resulting in overexpression of WT KRAS protein. This study investigates potential targets to enhance the efficacy of SHP2 inhibition in KRAS-amplified GEA, including those within the MAPK pathway and upstream RTKs. In vitro and in vivo experiments demonstrate that pan-ERBB kinase inhibition has potent cytotoxicity. Additionally, the combination of CDK4/6 inhibition with SHP2 inhibition shows greater efficacy in KRAS-amplified GEA compared to KRAS-mutant tumors. These findings suggest potential therapeutic combinations for clinical study in KRAS-amplified GEAs.
Article
Oncology
Qing Wang, Xiaolong Chen, Jianqing Zhang, Yuting Luo, Kehua Jiang
Summary: Urachal signet ring cell carcinoma is a rare and aggressive tumor. We reported a new case and conducted a literature review to enhance our understanding of this disease.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Aleksandr S. Martianov, Natalia V. Mitiushkina, Anastasia N. Ershova, Darya E. Martynenko, Mikhail G. Bubnov, Priscilla Amankwah, Grigory A. Yanus, Svetlana N. Aleksakhina, Vladislav I. Tiurin, Aigul R. Venina, Aleksandra A. Anuskina, Yuliy A. Gorgul, Anna D. Shestakova, Mikhail A. Maidin, Alexey M. Belyaev, Liliya S. Baboshkina, Aglaya G. Iyevleva, Evgeny N. Imyanitov
Summary: This study analyzed the factors influencing the distribution of actionable genetic alterations in colorectal carcinomas. The study found that there were differences in the distribution of certain genetic alterations based on patients' age and gender. BRAF mutation frequency also showed geographic variation. In addition, a small fraction of CRCs had simultaneous alterations in more than one driver gene.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Cell Biology
Avinashnarayan Venkatanarayan, Jason Liang, Ivana Yen, Frances Shanahan, Benjamin Haley, Lilian Phu, Erik Verschueren, Trent B. Hinkle, David Kan, Ehud Segal, Jason E. Long, Tony Lima, Nicholas P. D. Liau, Jawahar Sudhamsu, Jason Li, Christiaan Klijn, Robert Piskol, Melissa R. Junttila, Andrey S. Shaw, Mark Merchant, Matthew T. Chang, Donald S. Kirkpatrick, Shiva Malek
Summary: CRAF is necessary for the growth of KRAS mutant tumors and its dimerization plays a vital role. Lack of CRAF leads to sustained ERK activation and cell cycle arrest, and the CRAF-loss phenotype can be rescued by inhibiting MEK or ERK.
Article
Oncology
Haithem Zaafouri, Raja Jouini, Nizar Khedhiri, Fatma Khanchel, Mona Cherif, Meryam Mesbahi, Aziz Daghmouri, Wiem Mahmoudi, Soumaya Akremi, Meriam Sabbah, Yazid Benzarti, Dhafer Hadded, Dalila Gargouri, Mourad Ben Bader, Anis Ben Maamer
Summary: SRCC is a specific entity of gastric adenocarcinoma with increasing incidence. It is diagnosed pathologically as adenocarcinoma with a majority of signet-ring cells component. SRCC patients tend to be younger with a more infiltrative tumor character and a higher rate of postoperative chemotherapy. The overall survival of SRCC is worse in advanced cancer stages compared to non-SRCC.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2022)
Review
Oncology
Eabha O'Sullivan, Anna Keogh, Brian Henderson, Stephen P. Finn, Steven G. Gray, Kathy Gately
Summary: KRAS plays a crucial role in regulating cell growth and survival, and its activation is commonly observed in various types of tumors. Recent discoveries have identified a specific pocket in the structure of KRAS, leading to the development of inhibitors that target the G12C mutation. These inhibitors, such as sotorasib and adagrasib, have been approved for the treatment of non-small-cell lung cancer, but their efficacy may be limited by resistance mechanisms in cancer cells.
Article
Computer Science, Artificial Intelligence
Haochao Ying, Qingyu Song, Jintai Chen, Tingting Liang, Jingjing Gu, Fuzhen Zhuang, Danny Z. Chen, Jian Wu
Summary: Early detection of signet ring cell carcinoma can improve patient survival rates significantly, and deep learning methods are effective in automatically detecting pathological cells. However, limited and incomplete annotated data for deep learning model training are often due to uneven distribution of medical resources and tedious manual examination procedures for high-resolution images.
Article
Multidisciplinary Sciences
Kaja Kostyrko, Marta Roman, Alex G. Lee, David R. Simpson, Phuong T. Dinh, Stanley G. Leung, Kieren D. Marini, Marcus R. Kelly, Joshua Broyde, Andrea Califano, Peter K. Jackson, E. Alejandro Sweet-Cordero
Summary: In this study, researchers used RNAi screens to identify UHRF1 as an epigenetic regulator that is specifically vulnerable in KRAS mutant lung cancer cells. Knocking out UHRF1 selectively impaired the growth and induced apoptosis in KRAS mutant cells by causing global DNA hypomethylation and upregulation of tumor suppressor genes. In vivo experiments showed that UHRF1 knock-out inhibits tumor growth in KRAS-driven mouse lung cancer models. High UHRF1 expression in lung cancer patients is associated with low TSG expression and predicts worse outcomes in KRAS mutant tumors. These findings suggest that UHRF1 could be a potential target for therapeutic intervention in KRAS-driven cancer.
NATURE COMMUNICATIONS
(2023)
Review
Medicine, Research & Experimental
Amy Chang, Scott K. Sherman, James R. Howe, Vaibhav Sahai
Summary: Pancreatic neuroendocrine tumors (PNETs) are a heterogeneous group of neoplasms with varying treatment options. The treatment approach depends on factors such as tumor stage, grade and differentiation, symptoms, tumor burden, and rate of progression. Recent advancements in treatment have positively impacted patient care and prognosis.
ANNUAL REVIEW OF MEDICINE
(2022)
Meeting Abstract
Oncology
Devalingam Mahalingam, Benedito A. Carneiro, Howard Safran, Steven Francis Powell, Andrew L. Coveler, Elizabeth J. Davis, Andres Cervantes, Vaibhav Sahai, Neeltje Steeghs, Marisol Huerta, Jordan Berlin, Mary Frances Mulcahy, Francis J. Giles, Ludimila Cavalcante, Anwaar Saeed
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Vaibhav Sahai, Kent A. Griffith, Bruce Shih-Li Lin, Heloisa P. Soares, Sreenivasa R. Chandana, Oxana V. Crysler, Thomas Enzler, Mark Zalupski
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
Chandan Kumar-Sinha, Vaibhav Sahai
Summary: Patients with advanced hepatocellular or biliary cancers face a poor prognosis with limited efficacy from standard therapies. While precision medicine benefits a subset of biliary cancers, immunotherapy holds promise for hepatocellular carcinoma due to its immune-infiltrated microenvironment. The immunosuppressive and exhausted immune contexture in hepatobiliary cancers presents challenges for immunotherapy.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2022)
Article
Biochemistry & Molecular Biology
Sarah Owen, Emily Prantzalos, Valerie Gunchick, Vaibhav Sahai, Sunitha Nagrath
Summary: In this study, circulating tumor cells (CTCs) were isolated and analyzed to identify signatures related to survival and treatment response in pancreatic cancer patients. The findings highlight the importance of characterizing these markers to improve patient care and overcome treatment resistance mechanisms.
Article
Oncology
Kyoin Koo, Amy L. Pasternak, N. Lynn Henry, Vaibhav Sahai, Daniel L. Hertz
Summary: This study describes the current practice of pretreatment DPYD testing in the United States and identifies factors deterring oncologists from ordering testing. The results show that the clinical adoption of pretreatment DPYD testing is extremely limited in the United States, with low prevalence of DPD deficiency and lack of clinical practice guideline recommendations being the main barriers.
JCO ONCOLOGY PRACTICE
(2022)
Meeting Abstract
Oncology
A. Vogel, V. Sahai, A. Hollebecque, G. Vaccaro, D. Melisi, R. Al-Rajabi, S. Paulson, M. Borad, D. Gallinson, A. Murphy, D. Oh, E. Dotan, D. Catenacci, E. Van Cutsem, C. Lihou, H. Zhen, L. Veronese, G. Abou-Alfa
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
Vaibhav Sahai, Kent A. Griffith, Muhammad S. Beg, Walid L. Shaib, Devalingam Mahalingam, David B. Zhen, Dustin A. Deming, Mark M. Zalupski
Summary: This study found that the addition of nivolumab to chemotherapy or ipilimumab did not improve the 6-month progression-free survival (PFS) in patients with advanced biliary tract cancer (BTC). Although the median overall survival (OS) was less than 12 months in both treatment arms, the high OS rate at 2 years in Arm A suggests potential benefit for a small subset of patients.
Article
Biochemistry & Molecular Biology
Brittany Rupp, Sarah Owen, Harrison Ball, Kaylee Judith Smith, Valerie Gunchick, Evan T. Keller, Vaibhav Sahai, Sunitha Nagrath
Summary: As pancreatic cancer is the third deadliest cancer in the U.S., studying genetic alterations is crucial for understanding potential targets for cancer treatment. This study presents the Labyrinth-DEPArray pipeline for isolating and analyzing single circulating tumor cells (CTCs). Sequencing reveals copy number variations (CNVs) in single cells, including gains and losses of cancer-related genes. The pipeline combines antigen-free CTC isolation with single cell genomic analysis, offering a validated workflow for pancreatic cancer research.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Meeting Abstract
Oncology
A. Hollebecque, M. Borad, L. Goyal, A. Schram, J. O. Park, P. A. Cassier, S. D. Kamath, D. T. Wai Meng, E. Dotan, R. Kim, V. Sahai, D-Y. Oh, C-Y. Liao, M. Millward, D. Roda Perez, C. Ferte, R. Blakesley, B. Wolf, V. Subbiah, R. K. Kelley
ANNALS OF ONCOLOGY
(2022)
Letter
Oncology
Vaibhav Sahai, Mark M. Zalupski
Meeting Abstract
Oncology
Eileen S. Carpenter, Padma Kadiyala, Ahmed Elhossiny, Julia Freeman, Henry Dai, Valerie Gunchick, Filip Bednar, Marina Pasca di Magliano, Vaibhav Sahai
Meeting Abstract
Gastroenterology & Hepatology
Arndt Vogel, Vaibhav Sahai, Antoine Hollebecque, Gina M. Vaccaro, Davide Melisi, Raed Mal Rajabi, Andrew S. Paulson, Mitesh J. Borad, David Gallinson, Adrian G. Murphy, Do-Youn Oh, Efrat Dotan, Daniel V. Catenacci, Eric Van Cutsem, Christine F. Lihou, Huiling Zhen, Luisa Veronese, Ghassan K. Abou-Alfa
Meeting Abstract
Oncology
A. Schram, M. Borad, V. Sahai, S. Kamath, R. Kim, C. Y. A. Liao, D. Y. Oh, M. Ponz-Sarvise, J. Yachnin, S. A. Shell, P. Cassier, E. Dotan, V. Florou, V. Moreno, J. O. Park, D. Tai, O. Schmidt-Kittler, C. Ferte, L. Goyal, V. Subbiah
EUROPEAN JOURNAL OF CANCER
(2022)
Meeting Abstract
Gastroenterology & Hepatology
Rishi Das, Madeline R. Abbott, Matthew Schipper, Vaibhav Sahai, Filip Bednar, Scott Hadley, Joseph R. Evans, Theodore S. Lawrence, Kyle Cuneo
Article
Pathology
Juliana Mota Siqueira, Yoshitsugu Mitani, Camilla Oliveira Hoff, Flavia Bonini, Luana Guimaraes de Sousa, Mario L. Marques-Piubelli, Anurag Purushothaman, Mutsumi Mitani, Hui Dai, Shiaw-Yih Lin, Michael T. Spiotto, Ehab Y. Hanna, Daniel J. McGrail, Adel K. El-Naggar, Renata Ferrarotto
Summary: B7-H4 expression pattern varies among different types of salivary gland carcinomas, and high B7-H4 expression is associated with poor prognosis in adenoid cystic carcinoma.
Article
Pathology
Basile Tessier-Cloutier, Felix K. F. Kommoss, David L. Kolin, Kristyna Nemejcova, Dupreez Smith, Jennifer Pors, Colin J. R. Stewart, W. Glenn Mccluggage, William D. Foulkes, Andreas von Deimling, Martin Kobel, Cheng-Han Lee
Summary: This study provides a detailed analysis of the clinical, pathological, immunohistochemical, and molecular features of DDOC/UDOC. The majority of patients presented with extraovarian disease and had rapid disease progression resulting in high mortality rate.
Review
Pathology
Sophia J. Wagner, Christian Matek, Sayedali Shetab Boushehri, Melanie Boxberg, Lorenz Lamm, Ario Sada, Dominik J. E. Winter, Carsten Marr, Tingying Peng
Summary: Computational pathology research driven by deep learning faces challenges in reproducibility and reusability. Codebase with good documentation and robustness and generalizability of models are crucial. The reuse of computational pathology algorithms is limited, and their application in clinical settings is even rarer. This study evaluates 160 peer-reviewed articles, providing criteria for data and code availability and statistical analysis of results.
Article
Pathology
Andres M. Acosta, Lynette M. Sholl, Fiona Maclean, Chia-Sui Kao, Thomas M. Ulbright
Summary: This study assessed the clinicopathologic and genomic features of 14 cases of testicular sex cord-stromal tumors. The results showed that CTNNB1 mutations are rare in these tumors, and most of them have genomic alterations similar to testicular sex cord-stromal tumors with pure or predominant spindle cell components.
Article
Pathology
Toru Odate, Kaishi Satomi, Takashi Kubo, Yuko Matsushita, Toshihide Ueno, Akira Kurose, Kohei Shomori, Tokiko Nakai, Reiko Watanabe, Keiko Segawa, Shusa Ohshika, Naritomo Miyake, Sayaka Kudo, Tatsunori Shimoi, Eisuke Kobayashi, Motokiyo Komiyama, Seiichi Yoshimoto, Fumihiko Nakatani, Akira Kawai, Yasushi Yatabe, Shinji Kohsaka, Koichi Ichimura, Hitoshi Ichikawa, Akihiko Yoshida
Summary: Inflammatory rhabdomyoblastic tumors (IRMTs) are newly recognized skeletal muscle tumors with uncertain malignant potential. This study investigated 13 IRMTs using clinicopathologic, genetic, and epigenetic methods. The results showed specific histologic features and genetic mutations in these tumors, and most of them exhibited benign behavior.
Article
Pathology
Dale L. Davis, Adam C. Lechner, David B. Chapel, Jonathan C. Slack, Chrystalle Katte Carreon, Bradley J. Quade, Carlos Parra-Herran
Summary: The Amsterdam Consensus Statement introduced the term maternal vascular malperfusion (MVM) to classify a group of findings related to impaired maternal-placental circulation. The study found that features such as low placental weight, accelerated villous maturation, decidual arteriopathy, and infarcts are associated with adverse obstetrical outcomes, while the role of other features like distal villous hypoplasia, excess multinucleated trophoblast, and retroplacental hemorrhage needs further research.
Review
Pathology
Alain C. Borczuk
Summary: COVID-19 is an acute respiratory illness that can progress to acute respiratory distress syndrome. While most patients recover completely, some may experience persistent respiratory dysfunction, known as long COVID. The pathogenesis involves immune and cellular disturbances.
Article
Pathology
Annikka Weissferdt, Cheuk H. Leung, Heather Lin, Boris Sepesi, William N. William, Stephen G. Swisher, Tina Cascone, J. Jack Lee, Abujiang Pataer
Summary: Neoadjuvant treatment of non-small cell lung cancer challenges traditional processing of pathology specimens, and accurate evaluation of residual tumor is crucial for assessing treatment efficacy.
